Fulvestrant is an effective agent for the treatment of hormone receptor‑positive advanced breast cancer.

I. Common Side Effects of Fulvestrant

1. Injection Site Reactions

(1) Fulvestrant is administered by intramuscular injection. Injection site reactions are among the most common side effects.

(2) Clinical studies show that approximately 11.6% of patients treated with the 500 mg dose experience injection site pain.

(3) Some patients may develop more severe injection‑related neurological issues, including sciatica, neuralgia, and peripheral neuropathy.

(4) If leg numbness, tingling, or weakness occurs after injection, inform a healthcare professional immediately.

2. Gastrointestinal Reactions

(1) Gastrointestinal discomfort is common during fulvestrant treatment.

(2) Approximately 9.7% of patients experience nausea, 6% experience vomiting, 6% experience decreased appetite, and 5% experience constipation.

(3) These symptoms are usually more prominent at the beginning of treatment and may gradually improve with ongoing therapy.

3. Musculoskeletal Reactions

(1) Bone pain and arthralgia are common in patients receiving fulvestrant, with an incidence of approximately 9–10%.

(2) Patients may present with generalized bone pain, joint pain, or musculoskeletal discomfort, which may affect quality of daily life.

4. Systemic Reactions

(1) Fatigue and asthenia are frequently reported symptoms, occurring in about 8–11% of patients to varying degrees.

(2) In addition, approximately 7–8% of patients experience headache, and 6–7% experience hot flashes. Although not severe, these symptoms may affect the patient’s treatment experience.

5. Liver Function Abnormalities

(1) In clinical studies, more than 15% of patients developed elevated liver enzymes (ALT, AST, alkaline phosphatase), with 1–2% being grade 3–4 severe elevations.

(2) These changes are not dose‑related, but regular monitoring of liver function is required.

6. Special Side Effects with Combination Therapy

When fulvestrant is used in combination with a CDK4/6 inhibitor, the side‑effect profile changes:

(1) In combination with palbociclib: common adverse reactions include neutropenia (83%), leukopenia (53%), and infection (47%).

(2) In combination with abemaciclib: common adverse reactions include diarrhea (86%), fatigue (46%), and nausea (45%).

(3) In combination with ribociclib: common adverse reactions include neutropenia, infection, leukopenia, and cough.

II. Methods to Relieve Side Effects

1. Management of Injection Site Reactions

(1) A local cold compress may be applied after injection to reduce pain and discomfort.

(2) Avoid pressing or massaging the injection area.

(3) If severe pain or neurological symptoms occur, contact a healthcare professional immediately for evaluation.

(4) For each injection, healthcare professionals will select the proper site to avoid the sciatic nerve area.

2. Management of Gastrointestinal Symptoms

For nausea and decreased appetite, the following measures may be taken:

(1) Eat small, frequent meals and avoid fasting.

(2) Choose light, easily digestible foods.

(3) Avoid greasy, spicy, or overly sweet foods.

(4) Rest appropriately after meals; do not lie down immediately.

(5) For constipation, increase water intake and dietary fiber (e.g., vegetables, fruits, whole grains), and use mild laxatives under medical guidance.

3. Relief of Musculoskeletal Discomfort

(1) For bone pain and joint pain, appropriate analgesics may be used under the guidance of a physician.

(2) Gentle activities such as walking and stretching help maintain joint flexibility, but strenuous exercise should be avoided.

(3) Warm compresses or gentle massage may also relieve local discomfort.

4. Strategies for Fatigue and Asthenia

(1) Arrange a reasonable schedule and ensure adequate sleep.

(2) Perform important activities when energetic and avoid overexertion.

(3) Mild physical activity such as walking may help improve fatigue.

(4) If fatigue severely affects daily life, inform a doctor for evaluation.

5. Monitoring and Management of Liver Function Abnormalities

(1) Undergo regular liver function tests as prescribed, usually monthly or per treatment cycle.

(2) Seek immediate medical attention if symptoms such as worsening fatigue, significant loss of appetite, yellowing of the skin or sclera occur.

(3) Avoid concurrent use of medications or health products that may affect liver function.

6. Special Precautions with Combination Therapy

(1) When combined with palbociclib, regular blood count monitoring and infection prevention are required.

(2) When combined with abemaciclib, diarrhea is a common side effect; maintain adequate hydration and use antidiarrheal medications if necessary.

When combined with ribociclib, ECG and electrolyte monitoring are required.

III. Proper Storage of Fulvestrant

1. Temperature Requirements

(1) Fulvestrant injection must be stored under refrigeration at a temperature between 2°C and 8°C (36°F and 46°F).

(2) Freezing is strictly prohibited. Excessive heat or freezing may compromise drug stability and efficacy.

2. Light Protection

(1) Fulvestrant is light‑sensitive and must be kept in the original carton until use.

(2) This effectively protects the drug from direct light and maintains stable efficacy.

For further relevant information, please refer to the Fulvestrant Prescribing Information.